JNJ
237.44
-1.07%↓
UNH
277.52
+0.4%↑
TMO
544.35
+0.43%↑
ABT
110.94
+0.11%↑
ISRG
491.54
+0.88%↑
JNJ
237.44
-1.07%↓
UNH
277.52
+0.4%↑
TMO
544.35
+0.43%↑
ABT
110.94
+0.11%↑
ISRG
491.54
+0.88%↑
JNJ
237.44
-1.07%↓
UNH
277.52
+0.4%↑
TMO
544.35
+0.43%↑
ABT
110.94
+0.11%↑
ISRG
491.54
+0.88%↑
JNJ
237.44
-1.07%↓
UNH
277.52
+0.4%↑
TMO
544.35
+0.43%↑
ABT
110.94
+0.11%↑
ISRG
491.54
+0.88%↑
JNJ
237.44
-1.07%↓
UNH
277.52
+0.4%↑
TMO
544.35
+0.43%↑
ABT
110.94
+0.11%↑
ISRG
491.54
+0.88%↑
24h
Current
Min
Max
Income | -75M -544K |
|---|---|
Sales | 182K 26M |
P/E Sector Avg | 19.915 84.243 |
Profit margin | -2.087 |
Employees | 59 |
EBITDA | 73M 1.5M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +190.7% upside |
Next Earnings | 10 Mar 2026 |
|---|
Market Cap | -46M 527M |
|---|---|
Previous open | 0 |
Previous close | 0 |
Past performance is not a reliable indicator of future results.
27 Feb 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 25 USD 190.7%
High 26 USD
Low 24 USD
Based on 3 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
3 ratings
3
Buy
0
Hold
0
Sell
Based on 3 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$